OGB 21502
Alternative Names: OGB-21502Latest Information Update: 28 Dec 2023
At a glance
- Originator Onegene Biotechnology
- Class Anti-inflammatories; Hepatoprotectants; Recombinant fusion proteins
- Mechanism of Action Fibroblast growth factor 21 modulators; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists; Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 10 Nov 2023 Pharmacodynamics data from a Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 07 Sep 2023 Onegene Biotechnology plans to file an IND application in 2024
- 21 Jun 2023 Pharmacodynamics data from preclinical trial in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)